Web13. jan 2024 · 5%以上の患者で確認された グレード 3~4の 有害事象 (AE)は、 好中球減少症 がペルツズマブ+トラスツズマブ併用群の13%に対してPhesgo群で14%、好中球数減少がペルツズマブ+トラスツズマブ併用群の12%に対してPhesgo群で11%、発熱性好中球 … Web13. júl 2024 · Phesgo可在单剂量药瓶中使用,初始负荷剂量约需八分钟,随后的每次维持剂量约需五分钟。顺序注入负荷剂量需约150分钟使用标准IV配方配制Perjeta®和Herceptin®,并在60-150分钟之间进行两种药物的后续维护输注。
Phesgo European Medicines Agency
Web13. okt 2024 · DESCRIPTION. PHESGO is a combination of pertuzumab, trastuzumab, and hyaluronidase. Pertuzumab is a recombinant humanized monoclonal antibody that targets the extracellular dimerization domain (Subdomain II) of the human epidermal growth factor receptor 2 protein (HER2). Pertuzumab is produced by recombinant DNA technology in a … Web1. nov 2024 · If Phesgo is administered during pregnancy, or if a patient becomes pregnant while receiving Phesgo or within 7 months following the last dose of Phesgo, health care providers and patients should immediately report Phesgo exposure to Genentech at 1-888-835-2555. Risk Summary. Phesgo can cause fetal harm when administered to a pregnant … saaho for free
Pakketadvies sluisgeneesmiddel pertuzumab en trastuzumab (Phesgo…
Web8. aug 2024 · Phesgo is a cancer medicine that is used alone or with other medicines to treat early-stage breast cancer. Phesgo is also used to treat HER2-positive breast cancer … Web14. júl 2024 · How to pronounce - PHESGO 61 views Jul 14, 2024 0 Dislike Share Save Pronunciation Sample 2.16K subscribers How to pronounce - PHESGO Show more … Web24. dec 2024 · 罗氏(Roche)近日宣布,欧盟委员会(EC)已批准Phesgo(pertuzumab/trastuzumab/hyaluronidase)皮下注射液,该药是由Perjeta(pertuzumab,帕妥珠单抗)和Herceptin(trastuzumab,曲妥珠单抗)与透明质酸酶(hyaluronidase)构成的一种固定剂量组合(FDC),通过皮下注射(SC)给药,联 … is ghilline maxwell american